Jiri Damborsky and Team: Thrombolytic Proteins Profiling: High-Throughput Activity, Selectivity, And Resistance Assays
Jiri Damborsky, Head of Research Group at ICRC, Loschmidt Laboratories and Masaryk University, posted on LinkedIn:
”STROKE – Thrombolytic proteins profiling: High-throughput activity, selectivity, and resistance assays
Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop
Published: October 4, 2025, FEBS Open Bio.
Read here.
We introduce optimized high-throughput assays for rapid and reliable screening of thrombolytic enzymes – enabling detailed insights into activity, fibrin selectivity, and inhibition resistance.
Cardiovascular and thrombotic diseases remain one of the world’s top health challenges. In our latest work, we introduce a comprehensive set of high-throughput biochemical assays that enable robust screening and detailed characterization of thrombolytic biomolecules – including activity, fibrin selectivity, clot binding, and inhibition resistance.
Using alteplase and tenecteplase as model enzymes, we demonstrate how these assays can accelerate the development of safer and more effective thrombolytic drugs. Our results confirm that tenecteplase outperforms alteplase in fibrin selectivity and inhibition resistance, supporting its growing clinical relevance.”
Title: Thrombolytic proteins profiling: High-throughput activity, selectivity, and resistance assays
Authors: Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop
Stay informed with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia